We are live on ! Find out more
SCM

Silverarc Capital Management Portfolio holdings

AUM $962M
1-Year Est. Return 524.64%
This Fund
S&P 500
This Quarter Est. Return
+18.72%
1 Year Est. Return
+524.64%
3 Year Est. Return
+2,765.44%
5 Year Est. Return
+10,523.08%
10 Year Est. Return
–
AUM
$445M
AUM Growth
+$21.4M
Cap. Flow
-$1.93M
Cap. Flow %
-0.43%
Top 10 Hldgs %
46.96%
Holding
84
New
14
Increased
27
Reduced
18
Closed
13
Avg Time Held Equity + Options
3.9 quarters
Top 10 Avg Time Held Equity + Options
1.4 quarters
Top 20 Avg Time Held Equity + Options
2 quarters
Avg Time Held Equity only
3.9 quarters
Top 10 Avg Time Held Equity only
1.4 quarters
Top 20 Avg Time Held Equity only
2.2 quarters

Top Buys

Rank Stock Value
1
INSM icon
Insmed
INSM
+$15.3M
2
CNTA
Centessa Pharmaceuticals
CNTA
+$9.12M
3
PTGX icon
Protagonist Therapeutics
PTGX
+$5.93M
4
VCYT icon
Veracyte
VCYT
+$5.3M
5
PCVX icon
Vaxcyte
PCVX
+$5.23M

Top Sells

Rank Stock Value
1
MORF icon
Morphic Holding, Inc. Common Stock
MORF
+$16.6M
2
CRBP icon
Corbus Pharmaceuticals
CRBP
+$8.83M
3
CLDX icon
Celldex Therapeutics
CLDX
+$8.76M
4
NUVL icon
Nuvalent
NUVL
+$7.82M
5
URGN icon
UroGen Pharma
URGN
+$2.98M

Sector Composition

Rank Sector Weight
1 Healthcare 99.65%
2 Miscellaneous 0.35%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow Held Since
NUVL icon
1
DELISTED
Nuvalent
NUVL
$38M 8.53%
371,441
-94,269
-20% -$7.82M
2023 Q4
3 quarters
MRUS icon
2
DELISTED
Merus
MRUS
$31.7M 7.13%
635,439
+11,811
+2% +$617K
2021 Q1
14 quarters
INSM icon
3
Insmed
INSM
$21.1B
$25.4M 5.7%
347,695
+207,695
+148% +$15.3M
2020 Q4
15 quarters
RNAM
4
DELISTED
Avidity Biosciences
RNAM
$21.8M 4.91%
475,555
-42,179
-8% -$1.83M
2024 Q1
2 quarters
ERAS icon
5
Erasca
ERAS
$5.17B
$19M 4.26%
6,946,488
-870,438
-11% -$2.45M
2024 Q1
2 quarters
AKRO icon
6
DELISTED
Akero Therapeutics
AKRO
$18.4M 4.12%
639,840
+14,753
+2% +$385K
2022 Q2
9 quarters
VCYT icon
7
Veracyte
VCYT
$3.47B
$16M 3.6%
470,565
+188,317
+67% +$5.3M
2021 Q1
14 quarters
RYTM icon
8
Rhythm Pharmaceuticals
RYTM
$5.96B
$13.4M 3.01%
255,578
+70,916
+38% +$3.4M
2023 Q2
5 quarters
COGT icon
9
Cogent Biosciences
COGT
$4.87B
$13.2M 2.96%
1,221,362
+15,148
+1% +$147K
2020 Q4
15 quarters
ITCI icon
10
DELISTED
Intra-Cellular Therapies Inc.
ITCI
$12.2M 2.75%
167,110
-25,235
-13% -$1.9M
2020 Q4
15 quarters
CNTA
11
DELISTED
Centessa Pharmaceuticals
CNTA
$11.9M 2.67%
+744,592
New +$9.12M
2024 Q3
0 quarters
URGN icon
12
UroGen Pharma
URGN
$1.87B
$11.4M 2.57%
901,129
-200,871
-18% -$2.98M
2023 Q3
4 quarters
ORIC icon
13
Oric Pharmaceuticals
ORIC
$1.17B
$11.3M 2.53%
1,099,490
+23,678
+2% +$234K
2022 Q2
9 quarters
PSTX icon
14
DELISTED
Poseida Therapeutics, Inc. Common Stock
PSTX
$10.5M 2.37%
3,687,548
+79,549
+2% +$246K
2021 Q4
11 quarters
VRNA
15
DELISTED
Verona Pharma
VRNA
$10M 2.25%
348,866
+44,233
+15% +$1.09M
2024 Q1
2 quarters
ALNY icon
16
Alnylam Pharmaceuticals
ALNY
$29.9B
$9.84M 2.21%
35,774
-226
-0.6% -$58.8K
2024 Q2
1 quarter
GERN icon
17
Geron
GERN
$771M
$8.18M 1.84%
1,801,561
+802,291
+80% +$3.65M
2024 Q1
2 quarters
SNDX icon
18
Syndax Pharmaceuticals
SNDX
$1.25B
$7.29M 1.64%
378,746
+8,746
+2% +$181K
2024 Q2
1 quarter
PCVX icon
19
Vaxcyte
PCVX
$10.5B
$6.91M 1.55%
60,500
+58,000
+2,320% +$5.23M
2024 Q2
1 quarter
KALV icon
20
DELISTED
KalVista Pharmaceuticals
KALV
$6.65M 1.49%
574,558
+13,675
+2% +$172K
2023 Q1
6 quarters
PTGX icon
21
Protagonist Therapeutics
PTGX
$8.96B
$6.6M 1.48%
+146,657
New +$5.93M
2024 Q3
0 quarters
CCCC icon
22
C4 Therapeutics
CCCC
$342M
$6.54M 1.47%
1,147,891
-294,950
-20% -$1.78M
2024 Q1
2 quarters
SRPT icon
23
Sarepta Therapeutics
SRPT
$1.74B
$6.4M 1.44%
51,245
+9,245
+22% +$1.28M
2024 Q2
1 quarter
BDSX icon
24
Biodesix
BDSX
$264M
$6.34M 1.42%
178,055
+87,607
+97% +$3.01M
2024 Q2
1 quarter
ELUT icon
25
Elutia
ELUT
$34.2M
$6.27M 1.41%
1,645,808
+42,228
+3% +$165K
2024 Q1
2 quarters
1
2 3 4

Similar funds

LGP
Leonard Green & Partners Los Angeles, California $962M AUM 35.11% 1-Year Est. Return
PL
Parthenon LLC Louisville, Kentucky $962M AUM 27.46% 1-Year Est. Return
LAM
L2 Asset Management Wayland, Massachusetts $963M AUM 38.06% 1-Year Est. Return
ACP
Aviance Capital Partners Naples, Florida $963M AUM 32.56% 1-Year Est. Return
GIG
Goodnow Investment Group Darien, Connecticut $964M AUM 2.51% 1-Year Est. Return
AAP
Ardsley Advisory Partners Stamford, Connecticut $960M AUM 207.76% 1-Year Est. Return
BEAM
Baker Ellis Asset Management Vancouver, Washington $964M AUM 39.24% 1-Year Est. Return
RAM
Ramirez Asset Management New York $960M AUM 30.25% 1-Year Est. Return

Silverarc Capital Management's Q3 2024 Portfolio in Review

As of Q3 2024, Silverarc Capital Management held 84 positions worth $445M, up 5.1% from $424M the previous quarter. Its ten largest holdings account for 47% of the portfolio.

Silverarc Capital Management's Q3 2024 filing shows 14 new, 27 increased, 18 reduced and 13 closed positions. Its largest new stake was Centessa Pharmaceuticals: 744,592 shares worth $11.9M. The largest sale was Morphic Holding, Inc. Common Stock, an estimated $16.6M.

By sector, the portfolio is most concentrated in Healthcare at 100% of assets, up from 96% a quarter earlier, followed by Miscellaneous.

  • Silverarc Capital Management's largest Q3 2024 buy was Centessa Pharmaceuticals: 744,592 shares worth $11.9M.
  • Silverarc Capital Management added most to Insmed in Q3 2024, an estimated $15.3M increase.
  • Silverarc Capital Management's biggest Q3 2024 reduction was Celldex Therapeutics, cutting an estimated $8.76M.
  • Silverarc Capital Management fully exited Morphic Holding, Inc. Common Stock in Q3 2024, selling an estimated $16.6M.
  • Silverarc Capital Management's ten largest holdings make up 47% of its $445M portfolio in Q3 2024.
  • Silverarc Capital Management opened 14 new positions and closed 13 in Q3 2024.
  • Silverarc Capital Management's portfolio value rose 5.1% quarter-over-quarter to $445M.

Based on Silverarc Capital Management's 13F filing for Q3 2024, filed 14 Nov 2024.